Archives

by in
Entry Author Date Location
NephroGenex Preps $30M Stock Offering to Expand Kidney Drug Trial 05/01/15 Raleigh Durham
Xbiotech’s $76M Offering Sets Course for Late-Stage Cancer Studies 04/15/15 Texas
HAP Innovations Tackles Missed Meds with Automated Dispenser 04/14/15 Raleigh Durham
Fresh Off Boston Move, CoLucid Plots IPO For Migraine Drug Push 03/31/15 Raleigh Durham
Allergen Takes $80M Series B for Phase 3 Peanut Allergy Trial 03/12/15 San Francisco
Heat Biologics Launches $10M Stock Offering; CFO To Move On 03/11/15 Raleigh Durham
DARA BioSciences Nabs U.S. Rights to Oral Thrush Drug 03/10/15 Raleigh Durham
Raleigh-Durham Roundup: MaxPoint, Targacept, Frontier Capital, & More 03/09/15 Raleigh Durham
Duke Cardiologist Califf Appointed FDA Deputy Commissioner 01/26/15 Raleigh Durham
Migraine Drug Developer CoLucid Lands $37.1M for Phase 3 Trial 01/13/15 Raleigh Durham
Cempra Antibiotic Hits Pneumonia Goals; $100M Stock Sale Planned 01/06/15 Raleigh Durham
How Ebola Drug Trials Today Could Shape Future Drug Development 12/09/14 Raleigh Durham
Pozen, Sanofi Terminate Drug Pact Ahead of FDA Approval Decision 12/01/14 Raleigh Durham
Raleigh-Durham Roundup: Appia, Chimerix, Ascletis & More 11/17/14 Raleigh Durham
Chimerix Plans $105M Stock Offering to Finance Ebola Drug Trials 10/30/14 Raleigh Durham
BioPontis, Reborn as Nonprofit, Takes On Rare Disease Drugs 10/20/14 Raleigh Durham
Chimerix Antiviral to Start in Ebola Clinical Trial 10/16/14 Raleigh Durham
Raleigh-Durham Roundup: Targacept, Chimerix, Red Hat, & More 10/13/14 Raleigh Durham
Orphan Drug From Scioderm Aims to Treat Rare Skin Disease 10/07/14 Raleigh Durham
Texas Ebola Patient Gets Chimerix Drug, Clinical Trials Planned 10/06/14 Raleigh Durham
West Coast Biotech Roundup: Halozyme, Nektar, Allozyne, Novo & More 09/18/14 Seattle
West Coast Biotech Roundup: Scripps, Trounson, Versant, Gilead, & More 07/10/14 San Francisco
Overstreet, Winner in Startup Tax Battle, Gets $2M for AdverseEvents 04/16/14 San Francisco
FDA Approves First Drug for Exelixis of South San Francisco 11/29/12 San Francisco
Forest Labs, Adamas in Pact to Develop Alzheimer’s Drug Combo 11/15/12 New York
Aveo Cuts Staff, Announces 3rd Quarter Loss 10/31/12 Boston
Xconomist of the Week: NPS’s Francois Nader Shares Lessons Learned 10/25/12 New York
East Coast Life Sciences Roundup: Orphan Drugs, Financings, More 10/19/12 New York
FDA Staff Issues Positive Report for Aegerion’s Lomatapide 10/15/12 Boston
Exelixis and Onyx Await Their Cancer-Drug Fates 09/18/12 San Francisco
Page 1 of 2 next page »